Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 3918292, 6 pages
http://dx.doi.org/10.1155/2016/3918292
Research Article

Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 Examinations

1Department of Diagnostic Imaging, Radiant and Metabolic Therapy, Istituto Nazionale Tumori “Fondazione G. Pascale” IRCCS, 80131 Naples, Italy
2Department of Anesthesia, Endoscopy and Cardiology, Istituto Nazionale Tumori “Fondazione G. Pascale” IRCCS, 80131 Naples, Italy
3UOC Anestesia e Terapia Intensiva, Presidio Ospedaliero “Pineta Grande” Castel Volturno, 81100 Caserta, Italy
4Department of Hepatobiliary Surgical Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale” IRCCS, 80131 Naples, Italy

Received 24 February 2016; Revised 15 July 2016; Accepted 1 August 2016

Academic Editor: Marco Francone

Copyright © 2016 Vincenza Granata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M.-F. Bellin, “MR contrast agents, the old and the new,” European Journal of Radiology, vol. 60, no. 3, pp. 314–323, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. H. P. Niendorf, A. Alhassan, T. H. Balzer et al., “Safety and risk of gadolinium-DTPA: extended clinical experience after more than 20 million applications,” in Magnevist Monograph, R. Felix, N. Hosten, and H. Hricak, Eds., Blackwell Science, 3rd edition, 1998. View at Google Scholar
  3. The American College of Radiology, Manual on contrast media version. Version 10.2, 2016, http://www.acr.org/.
  4. H. Ersoy and F. J. Rybicki, “Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis,” Journal of Magnetic Resonance Imaging, vol. 26, no. 5, pp. 1190–1197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. K. L. Nelson, L. M. Gifford, C. Lauber-Huber, C. A. Gross, and T. A. Lasser, “Clinical safety of gadopentetate dimeglumine,” Radiology, vol. 196, no. 2, pp. 439–443, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. V. M. Runge, “Safety of approved MR contrast media for intravenous injection,” Journal of Magnetic Resonance Imaging, vol. 12, no. 2, pp. 205–213, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Petrillo, R. Fusco, V. Granata et al., “Risk management in magnetic resonance: failure mode, effects, and criticality analysis,” BioMed Research International, vol. 2013, Article ID 763186, 5 pages, 2013. View at Publisher · View at Google Scholar
  8. European Society of Urogenital Radiology, ESUR Guidelines on Contrast Media. V. 9.0. European Society of Urogenital Radiology, 2015, http://www.esur.org/guidelines/.
  9. D. Kobayashi, O. Takahashi, T. Ueda, G. A. Deshpande, H. Arioka, and T. Fukui, “Risk factors for adverse reactions from contrast agents for computed tomography,” BMC Medical Informatics and Decision Making, vol. 13, article 18, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. H. H. Schild, C. K. Kuhl, U. Hübner-Steiner, I. Böhm, and U. Speck, “Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: a prospective randomized controlled trial,” Radiology, vol. 240, no. 1, pp. 56–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. H. Abujudeh, V. K. Kosaraju, and R. Kaewlai, “Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections,” American Journal of Roentgenology, vol. 194, no. 2, pp. 430–434, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. R. Dillman, J. H. Ellis, R. H. Cohan, P. J. Strouse, and S. C. Jan, “Frequency and severity of acute allergic-like reactions to gadolinium-containing IV contrast media in children and adults,” American Journal of Roentgenology, vol. 189, no. 6, pp. 1533–1538, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. A. Kirchin and V. M. Runge, “Contrast agents for magnetic resonance imaging: safety update,” Topics in Magnetic Resonance Imaging, vol. 14, no. 5, pp. 426–435, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. M. R. Prince, H. Zhang, Z. Zou, R. B. Staron, and P. W. Brill, “Incidence of immediate gadolinium contrast media reactions,” American Journal of Roentgenology, vol. 196, no. 2, pp. W138–W143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J.-W. Jung, H.-R. Kang, M.-H. Kim et al., “Immediate hypersensitivity reaction to gadolinium-based MR contrast media,” Radiology, vol. 264, no. 2, pp. 414–422, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Aran, K. W. Shaqdan, and H. H. Abujudeh, “Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections,” Clinical Radiology, vol. 70, no. 5, pp. 466–475, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Wedeking, K. Kumar, and M. F. Tweedle, “Dissociation of gadolinium chelates in mice: relationship to chemical characteristics,” Magnetic Resonance Imaging, vol. 10, no. 4, pp. 641–648, 1992. View at Publisher · View at Google Scholar · View at Scopus
  18. M. F. Tweedle, P. Wedeking, and K. Kumar, “Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats,” Investigative Radiology, vol. 30, no. 6, pp. 372–380, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Corot, J.-M. Idee, A.-M. Hentsch et al., “Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme,” Journal of Magnetic Resonance Imaging, vol. 8, no. 3, pp. 695–702, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. S. K. Morcos, “Extracellular gadolinium contrast agents: differences in stability,” European Journal of Radiology, vol. 66, no. 2, pp. 175–179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Rogosnitzky and S. Branch, “Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms,” BioMetals, vol. 29, no. 3, pp. 365–376, 2016. View at Publisher · View at Google Scholar
  22. S. Barbieri, C. Schroeder, J. M. Froehlich, A. Pasch, and H. C. Thoeny, “High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification,” Contrast Media and Molecular Imaging, vol. 11, no. 3, pp. 245–250, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Stojanov, A. Aracki-Trenkic, and D. Benedeto-Stojanov, “Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents—current status,” Neuroradiology, vol. 58, no. 5, pp. 433–441, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-M. Idée, C. Berthommier, V. Goulas et al., “Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation,” Biometals, vol. 11, no. 2, pp. 113–123, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Mühler, M. Saeed, R. C. Brasch, and C. B. Higgins, “Hemodynamic effects of bolus injection of gadodiamide injection and gadopentetate dimeglumine as contrast media at MR imaging in rats,” Radiology, vol. 183, no. 2, pp. 523–528, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Bøkenes, S. O. Hustvedt, and H. Refsum, “Comparison of cardiovascular changes after administration of gadodiamide injection and gadopentetate dimeglumine in dogs,” Academic Radiology, vol. 4, no. 3, pp. 204–209, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Pirovano, D. B. Goodman, U. Halemane, C. Venetianer, M. A. Kirchin, and A. Spinazzi, “Cardiac electrophysiologic monitoring after injection of gadobenate dimeglumine versus placebo in healthy volunteers and patients with cardiovascular disease,” Radiology, vol. 233, no. 2, pp. 555–565, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. H. P. Niendorf, J. C. Dinger, J. Haustein, I. Cornelius, A. Alhassan, and W. Clauß, “Tolerance data of Gd-DTPA: a review,” European Journal of Radiology, vol. 13, no. 1, pp. 15–20, 1991. View at Publisher · View at Google Scholar · View at Scopus
  29. K. J. Murphy, J. A. Brunberg, and R. H. Cohan, “Adverse reactions to gadolinium contrast media: a review of 36 cases,” American Journal of Roentgenology, vol. 167, no. 4, pp. 847–849, 1996. View at Publisher · View at Google Scholar · View at Scopus